New discovery may expand availability of bone marrow transplants by stopping fatal complications

February 1, 2010

If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology, they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.

"We hope that this study is the first step in the development and implementation of a new treatment for graft-versus-host disease," said Courtney M. Lappas, Ph.D., one of the scientists involved in the study. "This is important clinically because it could potentially minimize the risks associated with bone marrow transplantation, making these potentially curative transplants safer and more widely used in individuals with inherited immunodeficiency diseases."

Scientists performed bone marrow transplants using two genetically different strains of mice, causing graft-versus-host disease in the recipients. Some of recipient mice were then treated with ATL146e and others were given a . In mice treated before the disease took hold, the severity of graft-versus-host disease was reduced, leading to a significant decrease in and an increase in survival. In mice that already had graft-versus-host disease, treatment with ATL146e reversed the disease.

"Bone marrow transplants have saved thousands of lives, but for some this lifesaving therapy can become fatal," said John Wherry, Ph.D., Deputy Editor of the . "This research is very exciting because ultimately, it might improve the safety of bone marrow transplants and perhaps even open up new opportunities for this therapy in other diseases."

More information: Courtney M. Lappas, Po-Ching Liu, Joel Linden, Elizabeth M. Kang, and Harry L. Malech. Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J Leukoc Biol 2010 87: 345-354.

Related Stories

Recommended for you

Natural compound reduces signs of aging in healthy mice

October 27, 2016

Much of human health hinges on how well the body manufactures and uses energy. For reasons that remain unclear, cells' ability to produce energy declines with age, prompting scientists to suspect that the steady loss of efficiency ...

A metabolic switch to turn off obesity

October 27, 2016

You've tried all the diets. No matter: you've still regained the weight you lost, even though you ate well and you exercised regularly! This may be due to a particular enzyme in the brain: the alpha/beta hydrolase domain-6 ...

Mitochondria control stem cell fate

October 27, 2016

What happens in intestinal epithelial cells during a chronic illness? Basic research conducted at the Chair of Nutrition and Immunology at the Technical University of Munich (TUM) addressed this question by generating a new ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.